MILÁN y SAN MATEO, California–(BUSINESS WIRE)–Dompé, empresa biofarmacéutica líder con operaciones en Italia y Estados Unidos, ha anunciado el inicio de la inclusión de los primeros pacientes en un estudio de fase 3 de isociclosporina para el tratami…
Uncategorized
Leos ECP system show promise for standalone glaucoma surgery
ORLANDO — In this exclusive Healio Video Perspective from the American Academy of Ophthalmology meeting, Steve R. Sarkisian Jr., MD, discusses the Leos endoscopic cyclophotocoagulation system.Sarkisian said the Leos system (BVI) allows surgeons to perf…
Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported that independent industry analysts have r…
Tenpoint Therapeutics, Ltd. to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that Henric Bjarke, Chief Executive …
Secukinumab Fails to Show Benefit in Graves’ Orbitopathy
Secukinumab does not show greater clinical efficacy than placebo in patients with moderate-to-severe Graves’ orbitopathy, according to the ORBIT study. Medscape News UK
Uncategorized
Dompé Doses First Patients in Europe and US in Phase 3 Study of Isocyclosporin for Atopic Keratoconjunctivitis
MILAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé advances a novel, dual-inhibitor into Phase 3 for AKC, a chronic inflammatory eye disease with no FDA-approved treatment options.